Suchergebnisse - "Garrigós, Laia"

PubPharm (23)

1

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Keyaerts, M. | Guiot, T. | +23

2

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

enthalten in: International journal of molecular sciences | 2024

von Franco-Mateos, E. | Souza-Egipsy, V. | García-Estévez, L. | +11

3

Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors : the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023

von Garcia-Donas, J. | Hurtado, A. | Garrigos, L. | +20

4

Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

enthalten in: Clinical and translational oncology | 2023

von Garcia-Donas, J. | Hurtado, A. | Garrigos, L. | +19

5

Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

enthalten in: Revista de oncología | 2023

von Garcia-Donas, J. | Hurtado, A. | Garrigos, L. | +19

6

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer : The DEBBRAH trial

enthalten in: Neuro-oncology | 2023

von Pérez-García, J. | Vaz Batista, M. | Cortez, P. | +16

7

Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response

enthalten in: Frontiers in immunology | 2023

von Aran, A. | Lázaro, G. | Marco, V. | +8

8

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer : Diversity or Clonality?

enthalten in: Cancers | 2022

von Aran, A. | Garrigós, L. | Curigliano, G. | +2

9

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond

enthalten in: Expert opinion on biological therapy | 2021

von Perez, J. | Garrigós, L. | Gion, M. | +4

CommentIn: Expert Opin Biol Ther. 2022 May;22(5):673-674. - PMID 35414305

10

COVID-19 in breast cancer patients : a subanalysis of the OnCovid registry

enthalten in: Therapeutic advances in medical oncology | 2021

von Garrigós, L. | Saura, C. | Martinez-Vila, C. | +65